Trial Profile
A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 May 2022
Price :
$35
*
At a glance
- Drugs Rozanolixizumab (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Therapeutic Use
- Acronyms MyCIDPchoice
- Sponsors UCB Biopharma
- 06 Apr 2021 Status changed from active, no longer recruiting to completed.
- 07 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 16 Jun 2020 Planned End Date changed from 1 Dec 2020 to 1 Jun 2021.